

BioSenic appoints CarKath SRL, represented by Mr Eric Halioua, as chairman of the board of directors

Saintes, Belgium, 25 September 2025, 07.00am – BioSenic (Euronext Brussels and Paris: BIOS) announces the cooptation by the board of directors of CarKath SRL, represented by its permanent representative Mr Eric Halioua, as an independent director and its appointed as chairman of the board, following the end of mandate of Innoste SA, represented by its permanent representative Mr Jean Stéphane.

Mr. Eric Halioua is an experienced executive with over 25 years in the life sciences sector, combining scientific expertise with strategic business acumen. Throughout his career, he has demonstrated his ability to create, finance, and lead innovative biotechnology companies. His governance experience and independent judgment will be key assets in guiding BioSenic's strategy, supporting informed decision-making, and safeguarding shareholders' interests

Together with Mrs Anne-Sophie Jourdain and Boletus Consulting BV, represented by its permanent representative Mr Seppe De Gelas – each of whom has been coopted by the board of directors for their experience and achievements in the legal and regulatory sectors (as announced on 4 August 2025, please see press release [here](#)) – they shall together constitute BioSenic's committee of independent directors. The cooptation of the three independent directors will be submitted to the next shareholders' meeting for confirmation of the cooptation and effective appointment of the three new independent directors.

The directors and the shareholders wish to express its gratitude to Innoste SA, permanently represented by Jean-Stéphenne, for his long-standing service as a director of BioSenic. Over many years, his leadership, integrity and sound judgement have made a lasting contribution to the company.

At the date of the present press release, the board of directors of BioSenic is composed as follows: Finsys Management SRL, represented by its permanent representative Mr Jean-Luc Vandebroek, managing director (*ad interim*); Iryl Partners SAS, represented by its permanent representative Mrs Revital Rattenbach (Aflalo), non-executive director; Capital Grand Est SAS, represented by its permanent representative Mr Jean-François Rax, non-executive director; Mrs Anne-Sophie Jourdain, independent director; Boletus Consulting BV, represented by its permanent representative Mr Seppe De Gelas, independent director; and CarKath SRL, represented by its permanent representative Mr Eric Halioua, independent director and chairman of the board.

About BioSenic

BioSenic is a biotechnology company with long-standing scientific and clinical legacy in orthopedics and regenerative therapies specialising in the clinical development of therapies in bone and cartilage repair.

BioSenic still owns some interests in its clinical assets ALLOB and JTA but is now focussing on a joint development with 4Moving Biotech on a GLP-1-based, disease-modifying therapy for veterinary use, specifically in post-ligament surgery recovery in dogs. Biosenic is also focusing on other new potential partnerships.

BioSenic is based in Avenue Léon Champagne 3, 1480 Saintes (Tubize), Belgium. Further information is available at <http://www.biosenic.com>.

For further information, please contact:

BioSenic SA

Finsys Management SRL, represented by its permanent representative Jean-Luc Vandebroek, managing director *ad interim*
investorrelations@biosenic.com

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the company or, as appropriate, the company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends

or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
